May 2nd 2024
Prateek Gulhati, MD, PhD, delivers takeaways from his presentation at the 2022 Annual Oncology Clinical Practice and Research Summit and key trials in pancreatic cancer that have moved the field forward.
Manmeet Singh Ahluwalia, MD, and his wife, Harneet Kaur Walia, MD, say that they learn from each other’s experiences and share in successes.
Breast oncologists recap findings from the 2022 San Antonio Breast Cancer Symposium.
March 7th 2024
Dr Kyriakopoulos sheds light on the potential synergy between masofaniten and enzalutamide when used in combination for patients with prostate cancer.
March 4th 2024
Camidge and Farmen talk through patient advocacy, Farmen’s cancer diagnosis, and the people who rallied around Farmen during the early days of her disease.
February 29th 2024
Dr Kang discusses the significance of the FDA approval of toripalimab for nasopharyngeal carcinoma and his anticipated use of the agent.
February 26th 2024
Dr Mims discusses the utility of emavusertib in acute myeloid leukemia and myelodysplastic syndrome and the rationale for the TakeAim Leukemia trial.
February 22nd 2024
Dr Tripathy discusses the unique aspects of the Miami Breast Cancer Conference that make it worth returning to year after year.
February 19th 2024
Drs Kitko and Patel discuss graft-versus-host disease recognition, treatment selection, and ongoing research with novel agents and biomarkers of response.
February 15th 2024
Drs Camidge and Kelley discuss the ways Dr Kelley’s passion for research guided his early career path.
February 12th 2024
Dr Galsky discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer.
February 8th 2024
Drs Jacob, Van Der Wall, and Wright-Browne discuss challenges and growth opportunities they have experienced throughout their careers.
February 5th 2024
Drs Lunning and Brander discuss the evolution of chronic lymphocytic leukemia management.
February 1st 2024
Drs Camidge and Okuyama Sasaki discuss the goals of safety net hospitals and the dynamics of helping low-income patients access cancer treatments.
January 29th 2024
Goyal, Bishop, Kelley, and Kuhlman discuss ways to prepare patients with cholangiocarcinoma for FGFR inhibitor–related adverse effects.
January 25th 2024
Dr Davids discusses the FDA approval of pirtobrutinib for patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.
January 22nd 2024
Drs Lunning and Maddocks discuss the management of MCL in the up-front setting.
January 18th 2024
Drs Camidge and Leland discuss various roles in the biotechnology field and the intricacies of starting a biotechnology company.
January 15th 2024
Dr Kasper discusses the FDA approval of nirogacestat for patients with progressing desmoid tumors; key efficacy, safety, and quality-of-life outcomes from the pivotal DeFi trial; and findings from an analysis investigating tumor volume and T2 hyperintensity changes with nirogacestat in patients enrolled in DeFi.
January 11th 2024
Drs Monk and Tarantino highlight current research investigating B7-H4–directed antibody-drug conjugates. in multiple solid tumor types.